p16-negative patients at 93.3% vs. 69.6%. Pathological N-status diered from clinical N-status in 36.8% of p16-negative patients vs. 31.6% of p16-positive patients. Occult metastatic disease was more common in p16-negative patients at 18.4% vs. 8.8% for p16-positive patients. Clinical detection sensitivity for extranodal extension was low
The results were published online ahead of print on May 12 in the Journal of Clinical Oncology. HPV16 was found in 81% of tumors, far and away the most common of the HPV subtypes; it was followed by HPV33, present in only 5.1% of tumors, and HPV18 and HPV58 in even fewer patients. Also, p16 positivity was seen in 92.9% of tumors.
Outcomes for p16 positive, HPV negative oropharyngeal SCC are not significantly different from p16 positive, HPV positive tumors and are significantly better than for p16 negative tumors. These results suggest that p16 immunohistochemistry alone is the best test to use for risk stratification in oro …
Oct 14, 2016 · In these studies, p16 positive was associated with significantly higher rates of progression and, in contrast, those low-grade lesions negative for p16 had a higher tendency to regress. 15, 16, 17
Sep 21, 2016 · The correlation between p16 immunophenotyping and HR-HPV as well as p16 INK4a molecular analyses confirmed that immunohistochemistry is a good surrogate for HR-HPV infection, with a p16 overexpression in all HPV-positive patients, and for p16 INK4a inactivation, with evidence of loss of p16 nuclear staining in all p16 INK4a-deleted patients
. 662 155 530 484 560 548 203 438
is p16 negative good or bad
